Gasdermin E–mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
GSDME-mediated target cell pyroptosis by CAR T cells activates macrophages to release proinflammatory cytokines for CRS.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Treatment for CRS and associated neurotoxicity primarily targets IL-6, likely arising from monocytes or activated endothelium [1, 6, 11–17].”
From Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm (2021) · cites this paper as [14]
In the citing paper
“Tumor lysis most likely also contributes to the cytokine storm through the induction of pyroptosis in target cells.55”
From Cytokine storm (2020) · cites this paper as [55]
Citations
Cites
Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death
Shi, J., Zhao, Y., Wang, K., Shi, X., Wang, Y., Huang, H., Zhuang, Y., Cai, T., Wang, F., & Shao, F. (2015) · Nature · doi:10.1038/nature15514 · Cited by 6,659
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Self-citationChimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin
Wang, Y., Gao, W., Shi, X., Ding, J., Liu, W., He, H., Wang, K., & Shao, F. (2017) · Nature · doi:10.1038/nature22393 · Cited by 3,199
U.S. Department of Health and Human Services
(2006) · Encyclopedia of Sexual Behavior and the Law · doi:10.4135/9781452240107.n226 · Cited by 3,170
Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death
Shi, J., Gao, W., & Shao, F. (2017) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2016.10.004 · Cited by 3,088
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Pore-forming activity and structural autoinhibition of the gasdermin family
Ding, J., Wang, K., Liu, W., She, Y., Sun, Q., Shi, J., Sun, H., Wang, D.-C., & Shao, F. (2016) · Nature · doi:10.1038/nature18590 · Cited by 2,771
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Cited by
Items 201–300 of 567
Zhang, Q., Zu, C., Jing, R., Feng, Y., Zhang, Y., Zhang, M., Lv, Y., Cui, J., Zhou, L., Meng, Y., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1125357 · Cited by 35
Self-citationCaspase-3/GSDME mediated pyroptosis: A potential pathway for sepsis
Jiao, C., Zhang, H., Li, H., Fu, X., Lin, Y., Cao, C., Liu, S., Liu, Y., & Li, P. A. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111022 · Cited by 36
Self-citationPyroptosis and the tumor immune microenvironment: A new battlefield in ovarian cancer treatment
Wang, A., Wang, Y., Du, C., Yang, H., Wang, Z., Jin, C., & Hamblin, M. R. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189058 · Cited by 34
Self-citationInkol, J. M., Westerveld, M. J., Verburg, S. G., Walsh, S. R., Morrison, J. A., Mossman, K. L., Worfolk, S. M., Kallio, K. L., Phippen, N. J., Burchett, R., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006781 · Cited by 33
Gasdermins in pyroptosis, inflammation, and cancer
Min, R., Bai, Y., Wang, N.-R., & Liu, X. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.04.003 · Cited by 31
Covalent Small Molecule Immunomodulators Targeting the Protease Active Site
Kim, H., Tagirasa, R., & Yoo, E. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00172 · Cited by 30
Boopathi, E., & Thangavel, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810126 · Cited by 32
Regulation of Pyroptosis by ncRNA: A Novel Research Direction
Gao, L., Jiang, Z., Han, Y., Li, Y., & Xiang, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.840576 · Cited by 30
Effect of tumor-associated macrophages on the pyroptosis of breast cancer tumor cells
Ji, X., Huang, X., Li, C., Guan, N., Pan, T., Dong, J., & Li, L. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01208-y · Cited by 31
“This process promotes the release of pro-inflammatory cytokines from TAM, triggering cytokine release syndrome (CRS), which, in turn, affects the pyroptosis process [66].”
BackgroundDevelopment of FAP-Targeted Chimeric Antigen Receptor NK-92 Cells for Non-Small Cell Lung Cancer
Yang, F., Wang, Y., Zhao, H., Huang, X., Fang, Y.-N., Chen, W.-Y., Han, R.-Z., Zhao, A., & Gao, J. (2023) · Discovery Medicine · doi:10.24976/discov.med.202335176.41 · Cited by 27
Self-citationKowalski, S., Karska, J., Łapińska, Z., Hetnał, B., Saczko, J., & Kulbacka, J. (2023) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30413 · Cited by 27
“Caspase‐3‐ dependent cleavage of GDSME can also be observed in the targets of CAR T cells, which can release Granzyme B as a mediator.(140)”
BackgroundRole of pyroptosis in diabetic cardiomyopathy: an updated review
Wang, G., Ma, T., Huang, K., Zhong, J.-H., Lu, S., & Li, J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1322907 · Cited by 34
“At the same time, Liu et al.also found that CAR-T cells can release granzyme to activate Caspase-3 in target cells, causing extensive pyroptosis (59).”
BackgroundYang, Q., Zhu, X., Huang, P., Li, C., Han, L., Han, Y., Gan, R., Xin, B., Tu, Y., Zhou, S., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.017 · Cited by 32
The role of pyroptosis in cancer: key components and therapeutic potential
Liu, Z., Xu, S., Chen, L., Gong, J., & Wang, M. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01932-z · Cited by 32
Pfister, F., Carnell, L. R., Löffler, L., Boosz, P., Schaft, N., Dörrie, J., Stein, R. A., Lenz, M., Spiecker, E., Huber, C. M., et al. (2025) · MedComm · doi:10.1002/mco2.70039 · Cited by 31
Chhunchha, B., Kubo, E., Lehri, D., & Singh, D. P. (2025) · Cells · doi:10.3390/cells14130994 · Cited by 35
“This has a great implication for antitumor responses [206,207].”
Tumor Secretome to Adoptive Cellular Immunotherapy: Reduce Me Before I Make You My Partner
Etxebeste-Mitxeltorena, M., del Rincón-Loza, I., & Martín-Antonio, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.717850 · Cited by 28
McKenzie, B., Khazen, R., & Valitutti, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.894306 · Cited by 29
“As it pertains to cancer therapy, pyroptosis has been shown to be instrumental in promoting therapeutically beneficial antitumor immunity in the context of both chemotherapy and immunotherapy; however, excess pyroptosis can be associated with inflammatory side-effects (80, 81, 110, 111).”
BackgroundCrosstalk between hypoxia-induced pyroptosis and immune escape in cancer: From mechanisms to therapy
Meybodi, S. M., Ejlalidiz, M., Manshadi, M. R., Raeisi, M., Zarin, M., Kalhor, Z., Saberiyan, M., & Hamblin, M. R. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104340 · Cited by 27
Zhu, J., Xiong, Y., Zhang, Y., Liang, H., Cheng, K., Lu, Y., Cai, G., Wu, Y. F., Fan, Y., Chen, X., et al. (2025) · 癌症:英文版 · doi:10.1002/cac2.70036 · Cited by 31
“For human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor T-cells (anti-hHER2-CAR-T cells), the CAR constructs targeting hHER2 and CD19 were designed as reported [27].”
Self-citationWu, L., Brzostek, J., Sankaran, S., Wei, Q., Yap, J., Tan, T. Y. Y., Lai, J., MacAry, P. A., & Gascoigne, N. R. J. (2021) · Cancers · doi:10.3390/cancers13040867 · Cited by 25
“The Gasdermin E (GSDME) signal pathway is activated, leading to pyroptosis of cancer cells and increased expression of damage-associated molecular pattern molecules (DAMPs), which in turn activate macrophages to release CRS-related cytokines [6].”
BackgroundZhang, X., & Yang, Q. F. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.705828 · Cited by 28
“A total of 34 pyroptosis-related genes were achieved through literature mining and are provided in Table 2 (Man and Kanneganti, 2015; Wang and Yin, 2017; Karki and Kanneganti, 2019; Xia et al., 2019; Ye et al., 2021).”
BackgroundSelf-citationApplication of nanotechnology in CAR-T-cell immunotherapy
Zeng, Q., Liu, Z., Niu, T., He, C., Qu, Y., & Qian, Z. (2022) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.107747 · Cited by 25
Noncoding RNA-mediated regulation of pyroptotic cell death in cancer
Wang, M., Zhang, Y., Chang, W., Zhang, L., Syrigos, K. N., & Li, P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1015587 · Cited by 30
Self-citationZhou, B., Ryder, C. B., Dubyak, G., & Abbott, D. W. (2022) · Science Signaling · doi:10.1126/scisignal.abl6781 · Cited by 26
Liu, P., Zhang, Z., Cai, Y., Yang, Y., Yuan, J., & Chen, Q. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115336 · Cited by 26
Self-citationProgress in the study of molecular mechanisms of cell pyroptosis in tumor therapy
Wang, D., & Wan, X. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110143 · Cited by 29
Unveiling the flames: macrophage pyroptosis and its crucial role in liver diseases
Ni, L., Chen, D., Zhao, Y., Ye, R., & Fang, P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1338125 · Cited by 26
Synergistically Augmenting Cancer Immunotherapy by Physical Manipulation of Pyroptosis Induction
Zhao, C., Zheng, T., Wang, R., Lin, X., Hu, Z., Zhao, Z., Dai, Z., & Sun, D. (2024) · Phenomics · doi:10.1007/s43657-023-00140-y · Cited by 33
“The Granzyme-B/GSDME and Granzyme-A/ GSDMB driven pyroptosis have also been discovered in nat-ural killer cells and lymphocytes, which may further enhance the immune response to cancer (Liu et al. 2020; Zhang et al. 2020; Zhou et al. 2020).”
BackgroundApplications of pyroptosis activators in tumor immunotherapy
Bao, X., Sun, M., Meng, L., Zhang, H., Yi, X., & Zhang, P. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101191 · Cited by 32
“Additionally, NK cells and CTLs can activate caspase-3 through the release of granzyme B (GZMB), which in turn cleaves GSDME to further facilitate extensive pyroptosis [70].”
BackgroundZhou, X., Chen, Z., Yu, Y., Li, M., Cao, Y., Prochownik, E. V., & Li, Y. (2024) · Advanced Science · doi:10.1002/advs.202403629 · Cited by 35
Targeting regulated cell death pathways in cancers for effective treatment: a comprehensive review
Saxena, R., Welsh, C. M., & He, Y.-W. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1462339 · Cited by 33
Macrophage pyroptosis and its crucial role in ALI/ARDS
Cai, Y., Shang, L., Zhou, F., Zhang, M., Li, J., Wang, S., Lin, Q., Huang, J., & Yang, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1530849 · Cited by 37
“Besides, CAR-T cell is able to rapidly activate caspase-3 in target cells by releasing granzyme B (GZMB), subsequently triggering caspase-3/GSDME-mediated pyroptosis (63).”
Fracture healing is delayed in the absence of gasdermin-interleukin-1 signaling
Sun, K., Wang, C., Xiao, J., Brodt, M. D., Yuan, L., Yang, T., Alippe, Y., Hu, H., Hao, D., Abu‐Amer, Y., et al. (2022) · eLife · doi:10.7554/elife.75753 · Cited by 25
“Other well-studied GSDMs include GSDMA and GSDME ( Liu et al., 2021 ; Zhang et al., 2020 ; Wang et al., 2021 ; Zhou et al., 2020 ).”
Novel pathophysiological insights into CAR-T cell associated neurotoxicity
Genoud, V., & Migliorini, D. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1108297 · Cited by 31
“Consequently, gasdermine D in surrounding macrophages will be cleaved by caspase 1, leading to cytokine release by macrophages, inducing CRS (4).”
BackgroundSecondary hemophagocytic lymphohistiocytosis in children (Review)
Benevenuta, C., Mussinatto, I., Orsi, C., & Timeus, F. S. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.12122 · Cited by 32
Zuo, Z., Yin, H., Zhang, Y., Xie, C., & Wang, Q. (2023) · Nature Communications · doi:10.1038/s41467-023-41335-1 · Cited by 29
“As mentioned, excessive lytic cell death may lead to cytokine release syndrome (CRS).”
InfluentialSelf-citationSakemura, R. L., Roman, C. M., Horvei, P., Siegler, E. L., Girsch, J. H., Sirpilla, O. L., Stewart, C. M., Yun, K., Can, İ., Ogbodo, E. J., et al. (2023) · Blood · doi:10.1182/blood.2022018905 · Cited by 28
The gasdermins: a pore-forming protein family expressed in the epidermis
Slaufova, M., Karakaya, T., Filippo, M. D., Hennig, P., & Beer, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1254150 · Cited by 30
To Kill But Not Be Killed: Controlling the Activity of Mammalian Pore-Forming Proteins
Krawczyk, P. A., Laub, M., & Kozik, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.601405 · Cited by 27
CAR-T cell therapy: practical guide to routine laboratory monitoring
Selim, A. G., Minson, A. G., Blombery, P. A., Dickinson, M. J., Harrison, S. J., & Anderson, M. A. (2021) · Pathology · doi:10.1016/j.pathol.2021.02.002 · Cited by 25
Gasdermin E-mediated programmed cell death: An unpaved path to tumor suppression
Wang, Y., Peng, J., Xie, X., Zhang, Z., Li, M., & Yang, M. W. (2021) · Journal of Cancer · doi:10.7150/jca.48989 · Cited by 27
“Abbreviations GSDME: gasdermin E; PCD: programmed cell death; PJVK: Pejvakin; DFNA5: deafness autosomal dominant 5; ICERE-1: inversely correlated to estrogen receptor expression; MT: mutant type; PRR: patternrecognition receptor; DAMPs: damaged-associated molecular patterns; PAMPs: pathogen-associated Journal of Cance…”
BackgroundInfluentialSelf-citationBeyond target cell death – Granzyme serine proteases in health and disease
Nüssing, S., Sutton, V. R., Trapani, J. A., & Parish, I. A. (2022) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2022.101152 · Cited by 25
New prospects of cancer therapy based on pyroptosis and pyroptosis inducers
Chen, Q., Sun, Y., Wang, S., & Xu, J. (2023) · APOPTOSIS · doi:10.1007/s10495-023-01906-5 · Cited by 25
“CAR-T cells rapidly activate caspase-3/GSDME-dependent pyroptosis in target cells by releasing granzyme B (GzmB) [61 ].”
Killer cells add fire to fuel immunotherapy
Nicolai, C. J., & Raulet, D. H. (2020) · Science · doi:10.1126/science.abc2502 · Cited by 24
Harnessing Pyroptosis for Cancer Immunotherapy
Bourne, C. M., & Taabazuing, C. Y. (2024) · Cells · doi:10.3390/cells13040346 · Cited by 30
“Mechanistically, Liu et al. reported that CAR T cells have higher levels of perforin and GzmB compared to existing CD8 + T cells, which allows CAR T cells, but not existing CD8 + T cells, to induce sufficient CASP3/GSDME processing to overcome membrane repair pathways and mediate pyroptosis [62].”
BackgroundInfluentialYin, H., Hu, X., Xie, C., Li, Y., Gao, Y., Zeng, H., Zhu, W., Xie, D., & Wang, Q. (2024) · Advanced Materials · doi:10.1002/adma.202401384 · Cited by 26
Self-citationProgrammed cell death in triple-negative breast cancer
Liu, Y., He, J., Chen, J., Chen, T., Li, W., Yang, Z., & Zeng, F. (2025) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-025-00789-5 · Cited by 31
Self-citationNanoparticle-based strategy in CAR-T cell immunotherapy: challenges, implications, and perspectives
Shang, D., Zhou, Z., Shi, R., Wang, Z., Zhang, P., Fu, P., Li, H., Cheng, G., Qin, H., Xie, Z., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02476-7 · Cited by 28
Self-citationGuo, H., Qian, L., & Cui, J. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0087 · Cited by 31
Pyroptosis in platelets: Thrombocytopenia and inflammation
Su, Y., Zhang, T., & Qiao, R. (2023) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24852 · Cited by 23
Self-citationMiao, L., Zhang, J., Xu, W., Qian, Q., Zhang, G., Yuan, Q., Lv, Y., Zhang, H., Shen, C., & Wang, W. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2338984 · Cited by 23
Nanomaterials Enhance Pyroptosis-Based Tumor Immunotherapy
Ji, F., Shi, C., Shu, Z., & Li, Z. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s457309 · Cited by 24
“6,7 With the deeper study of pyroptosis, more pathways may be discovered in the future.”
BackgroundRegulation of inflammatory processes by caspases
Beltrán‐Visiedo, M., Soler-Agesta, R., Sarosiek, K. A., Green, D. R., & Galluzzi, L. (2025) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-025-00869-6 · Cited by 27
Emerging Mechanisms and Targeted Therapy of Pyroptosis in Central Nervous System Trauma
Yang, B., Zhong, W., Gu, Y., & Li, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.832114 · Cited by 22
“In one study, apocynin, an NADPH oxidase inhibitor (Sparrey et al., 2016), significantly reduced oxidative stress and cell coke death after SCI and promoted motor function recovery and histological level (Liu Z et al., 2020).”
BackgroundThe role of pyroptosis and its crosstalk with immune therapy in breast cancer
Wu, L., Lu, H., Pan, Y., Liu, C., Wang, J., Chen, B., & Wang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.973935 · Cited by 30
“(48) initially stated that Granzyme B (GZMB) liberated from chimeric antigen receptor T cells allowed them to briefly stimulate caspase-3 in leukemic cells and cause GSDME-dependent pyroptosis in 2020.”
BackgroundDuck gasdermin E is a substrate of caspase-3/-7 and an executioner of pyroptosis
Li, H., Wang, X., Yu, L., Wang, J., Cao, Y., Ma, B., & Zhang, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1078526 · Cited by 20
“This is not surprising because, in human, granzyme B may also be an executioner of GSDME cleavage (32).”
BackgroundMcNerney, K. O., Hsieh, E. M., Shalabi, H., Epperly, R., Wolters, P. L., Hill, J. A., Gardner, R. A., Talleur, A. C., Shah, N. N., & Rossoff, J. E. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.10.006 · Cited by 22
Ri-Wen, Yang, Y., Zhang, T., Liu, C., & Yang, N. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107182 · Cited by 26
Self-citationLiu, R.-J., Yu, X.-D., Yan, S.-S., Guo, Z., Zao, X., & Zhang, Y. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5651 · Cited by 21
“In addition, there are alternative pathways of pyroptosis, such as via activated caspase‑3/8, that can mediate the cleavage of GSDME or GSDMC, releasing the N‑terminal PFD and eventually inducing pyroptosis (87‑91).”
BackgroundInfluentialSelf-citationLin, M., Zhang, C., Li, H., Li, K., Gou, S., He, X., Lv, C., & Gao, K. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1556990 · Cited by 34
“Unlike the classical and non-classical pathways, Caspase-3, activated by granzyme B secreted by chimeric antigen receptor T cells and chemotherapy drugs, cleaves the GSDME protein, causing N-GSDME to migrate to the cell membrane and form pores, thereby initiating pyroptosis (64 – 66).”
Fang, Y., Zhang, Y., Guo, C., Chen, C., Gao, H., Zhou, X., Liu, T., & Qian, Q. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.08.008 · Cited by 21
Self-citationNatural flavonoid sinensetin inhibits cisplatin-induced pyroptosis and attenuates intestinal injury
Li, Y., Wang, X., Lin, J., Wang, R., Zhang, B., Zhang, X., He, W., Gao, F., Song, D., Zhao, K., et al. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166637 · Cited by 20
Self-citationLi, P., Liu, Y., Liang, Y., Bo, J., Gao, S., Hu, Y., Hu, Y., Huang, H., Huang, X., Jing, H., et al. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2022.0585 · Cited by 20
Self-citationRole of gasdermin family proteins in cancers (Review)
Yang, X., & Tang, Z. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5548 · Cited by 22
“Liu et al (102) also reported a complication after chimeric antigen receptor (CAR) T‑cell therapy called cytokine release syndrome (CRS).”
InfluentialZhang, Z., Yang, Z., Wang, S., Wang, X., & Mao, J. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117367 · Cited by 25
Self-citationWang, J., Wang, Y., Xiao, H., Yang, W., Zuo, W., You, Z., Wu, C., & Bao, J. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.108050 · Cited by 23
“Moreover, pyrop-tosis can overcome the apoptotic resistance of tumor cells (15) and enhance antitumor immunity (16, 17).”
Endothelial Injury Following CAR-T Cell Immunotherapy for Hematological Malignancies
Demosthenous, C., Evangelidis, P., Gatsis, A., Mitroulis, I., Vakalopoulou, S., Vardi, A., Bountoura, S., Sakellari, I., & Gavriilaki, E. (2025) · Cancers · doi:10.3390/cancers17172876 · Cited by 28
“DAMPs can recruit and activate cells of endogenous innate immunity, including dendritic cells and macrophages, amplifying inflammatory responses and increasing the release of proinflammatory cytokines, such as interleukin-6 (IL-6) and interleukin-1 β (IL-1 β ) [20,21].”
Zhang, Y., Hu, R., Xie, X., & Li, Y. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06538-0 · Cited by 24
Self-citationJia, C., Zhang, Z., Tang, J., Cai, M., Zang, J., Shi, K., Sun, Y., Wu, J., Shi, H., Shi, W., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.781365 · Cited by 21
“In addition, GSDME aggravates adverse effects of certain anticancer regimens by causing pyroptosis-based normal tissue damage or cytokine release syndrome (Huang et al., 2020; Liu et al., 2020).”
BackgroundSelf-citationDeng, L., Jiang, L., Wei, N., Zhang, J., & Wu, X. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175363 · Cited by 19
Is Nuclear Factor Erythroid 2-Related Factor 2 a Target for the Intervention of Cytokine Storms?
Liu, Z., Deng, P., Liu, S., Bian, Y., Xu, Y., Zhang, Q., Wang, H., & Pi, J. (2023) · Antioxidants · doi:10.3390/antiox12010172 · Cited by 23
“Similarly, the activation of caspase-3 in target cells results in extensive pyroptosis in cytokine storms induced by CAR T-cell therapy [108].”
BackgroundLi, G. Q., Gao, S. X., Wang, F. H., Kang, L., Tang, Z. Y., & Xiao, D. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115019 · Cited by 26
Unlocking the potential of pyroptosis in tumor immunotherapy: a new horizon in cancer treatment
Yin, Q., Song, S.-Y., Bian, Y., Wang, Y., Deng, A., Lv, J., & Wang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1381778 · Cited by 21
“Furthermore, CAR-T cells have been shown to prompt rapid caspase-3 activation in target cells through granzyme B release, cleaving GSDME and inducing extensive pyroptosis in susceptible cells, underscoring the potential of GSDME and caspase-3 as targets for cancer therapy (64, 65).”
BackgroundSelf-citationDying to survive: harnessing inflammatory cell death for better immunotherapy
Cheng, L., Wang, Y., & Zhang, Y. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.01.012 · Cited by 19
Self-citationWang, X. W., He, X., Zhang, T., Liu, J., & Zhao, M. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06467-y · Cited by 25
“This process subsequently activates caspase-1 in macrophages, leading to the cleavage of gasdermin D (GSDMD) and the release of cytokines, which can result in CRS. Studies have correlated higher levels of GSDME and lactate dehydrogenase with the severity of CRS in patients [68 ].”
Self-citationIn vivo CAR-T cell therapy: New breakthroughs for cell-based tumor immunotherapy
Huang, Y., Cao, R. Y., Wang, S., Chen, X., Yü, P., & Zhang, Y. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2558403 · Cited by 23
“28,29 Antigen loss or escape is one of the barriers limiting the long-term efficacy of ex vivo CAR-T cell therapy.”
Self-citationDai, B., Zhang, R., Qi, S., Liu, L., Zhang, X., Deng, D., Zhang, J., Xu, Y., Liu, F., Liu, Z., et al. (2022) · Theranostics · doi:10.7150/thno.75966 · Cited by 20
“The cell membrane can be destroyed in several ways, including through punching holes in cell membranes (by gasdermin family proteins [16, 17], complement membrane attack complexes (MACs) [18-20], perforin [21], etc.”
BackgroundSelf-citationCAR-T cells for cancer immunotherapy
Xie, Y., Li, X., Wu, J., Zeng, H., Boucetta, H., Wang, B., Yang, P., & He, W. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.108202 · Cited by 20
Xiao, X., Cheng, Y., Zheng, X., Fang, Y., Zhang, Y., Sun, R., Tian, Z., & Sun, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1113303 · Cited by 19
“Cytokine release syndrome is mainly due to the activation of lymphocytes or monocytes to produce cytokines such as TNF, IL-6, and IL-1b, which then cause a severe systemic inflammatory response (9, 24, 42, 43).”
BackgroundSelf-citationHou, J., Li, T., Hsu, J.-M., Zhang, X., & Hung, M. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101833 · Cited by 21
Self-citationIgniting hope: Harnessing NLRP3 inflammasome-GSDMD-mediated pyroptosis for cancer immunotherapy
Li, L., Chen, L., & Sun, Z. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122951 · Cited by 21
Nanotechnology in Advancing Chimeric Antigen Receptor T Cell Therapy for Cancer Treatment
Kang, X., Mita, N., Zhou, L., Wu, S., Yue, Z., Babu, R. J., & Chen, P. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16091228 · Cited by 22
“Symptoms such as high fever [130], malaise, fatigue, myalgia, nausea, anorexia, [131,132], tachycardia, hypotension, [133], and multi-organ dysfunctions are driven by these mechanisms [134,135].”
BackgroundTargeting kinases that regulate programmed cell death: a new therapeutic strategy for breast cancer
Hong, Y. C., He, J., Deng, D., Liu, Q., Zu, X., & Shen, Y. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06367-9 · Cited by 21
“Liu et al. initially [50] reported that granzyme B (GZMB), released from chimeric antigen receptor T cells, can briefly stimulate caspase-3 in leukemia cells, leading to GSDME-dependent pyroptosis [66].”
Nano delivery of natural substances as prospective autophagy modulators in glioblastoma
Agarwal, S., & Maekawa, T. (2020) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2020.102270 · Cited by 17
Panoskaltsis, N., McCarthy, N. E., Stagg, A. J., Mummery, C. J., Husni, M., Arebi, N., Greenstein, D., Price, C. L., Al-Hassi, H. O., Koutinas, M., et al. (2021) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-020-02725-2 · Cited by 16
Yuan, Z., Jiang, G., Yuan, Y., Liang, Q., Hou, Y., Zhang, W., Tang, L., Fan, K., & Feng, W. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03335-9 · Cited by 19
“Unlike apoptosis, pyroptosis not only eliminates tumor cells but also activates antitumor immunity, making it an attractive therapeutic strategy [11–13].”
Manipulation of cancer cell pyroptosis for therapeutic approaches: challenges and opportunities
Miao, R., Wang, X., Zhang, J., Kang, Q., Liu, Q., Luo, X., Hou, J., & Gao, B. (2025) · Biomarker Research · doi:10.1186/s40364-025-00771-5 · Cited by 18
“Pyroptosis enhances antitumor immunity, but CD8 + T cells alone may not suffice; NK cells and macrophages likely play critical roles [8, 82].”
InfluentialPyroptosis in acute respiratory distress syndrome and pulmonary fibrosis
Liao, J., Liang, Y., Liu, Z., Qin, X., Zhang, J., Song, S., Huang, X., Cao, L., & Wang, Y. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118286 · Cited by 18
From pores to rupture: Structural basis and regulation of lytic cell death by gasdermins and NINJ1
Wang, C., Dreyer, B., Teran, E., & Ruan, J. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110698 · Cited by 19
Molecular mechanisms and therapeutic relevance of gasdermin E in human diseases
Wang, J., Ye, T., Wang, S., Wang, J., & Jin, Y. H. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110189 · Cited by 19
Genome editing of PD-L1 mediated by nucleobase-modified polyamidoamine for cancer immunotherapy
Wei, S., Shao, X., Liu, Y., Xiong, B., Cui, P., Liu, Z., & Li, Q. (2022) · Journal of Materials Chemistry B · doi:10.1039/d1tb02688g · Cited by 17
Self-citationPyroptosis-triggered pathogenesis: New insights on antiphospholipid syndrome
Tan, Y., Liu, Q., Li, Z., Yang, S., & Cui, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1155222 · Cited by 18
“GzmB has been identified to activate caspase-3, then caspase-3 cleaves GSDME and induces GSDME-mediated extensive pyroptosis (22).”
BackgroundLiang, X.-X., Liu, Q., Zhu, S., Li, Z., Chen, H., & Su, Z. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101796 · Cited by 18
“GSDME-mediated pyroptosis was an alternative pathway to suppress tumor by chemotherapy [8] and radiotherapy [11], and modulated immune microenvironment [12 – 15].”
BackgroundSelf-citationYang, X. Y., Cui, X., Wang, G., Zhou, M., Wu, Y., Du, Y., Li, X., & Xu, T. (2024) · Molecular Carcinogenesis · doi:10.1002/mc.23773 · Cited by 19
“14,15 GSDME ‐ dependent pyroptosis is common-place in tumor cells.”
Pyroptosis in Diabetic Peripheral Neuropathy and its Therapeutic Regulation
Mamun, A. A., Shao, C., Geng, P., Wang, S., & Xiao, J. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s465203 · Cited by 17
“136 Subsequently, the pyroptotic mechanism was mediated by Caspase-3 and GSDME, resulting in extensive pyroptosis.”
BackgroundGe, Y., Jiang, L., Yang, C., Dong, Q., Tang, C., Xu, Y., & Zhong, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1449696 · Cited by 17
In Vivo Monitoring and Magnetically‐Enhanced Delivery of CAR T‐Cells to Solid Tumor
Chen, H., Machado, A., An, D., Becharef, S., Autret, G., Ayollo, D., Razafindrakoto, S., Nizard, P., Carn, F., Luo, Y., et al. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202414368 · Cited by 17
Dong, X., Nie, J., Huang, A., Chen, L., Zang, E., Xiang, Z.-R., Hao, X., Yan, S., Ding, X., & Zhao, Y. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.01.028 · Cited by 19
“Excess pyroptotic cancer cells or normal cells cause tissue damage and severe excessive cytokine release [66,67].”
Neurotoxicity associated with chimeric antigen receptor T-cell therapy
Wronski, M., Wesselingh, R., Kazzi, C., Seery, N., Ko, K., Li, J. J., Tan, T., Simpson, T., Abbott, C., Fleming, S. A., et al. (2025) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2025.578717 · Cited by 17
“( DeAngelo et al., 2017) Cerebral oedema has been reported in clinical trials using CD19 CAR constructs in children and adults with B-ALL, LBCL and CLL. (Wang et al., 2020; Shah et al., 2021; Maude et al., 2018; DeAngelo et al., 2017; Locke et al., 2017) Furthermore, a case of delayed cerebral oedema at six months has…”
Influential
Metadata
- Authors
- Liu, Y., Fang, Y., Chen, X., Wang, Z., Liang, X., Zhang, T., Liu, M., Zhou, N., Lv, J., Tang, K., Xie, J., Gao, Y., Cheng, F., Zhou, Y., Zhang, Z., Hu, Y., Zhang, X., Gao, Q., Zhang, Y., & Huang, B.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Huazhong University of Science and Technology (CN)
- Wuhan Union Hospital (CN)
- Peking University People's Hospital (CN)
- Zhengzhou University (CN)
- Corresponding author
- Liu, Yuying
- Fang, Yiliang
- Chen, Xinfeng
- Huang, Bo
- ORCID
- Venue
- Science Immunology
- Published
- 2020-01-03
- Volume
- 5
- Issue
- 43
- ISSN
- 2470-9468 (ISSN-L)
- OpenAlex
- W2999534343
- Cited by
- 566
- References
- 45
- Citations by year
- 2026: 63 · 2025: 87 · 2024: 100 · 2023: 127 · 2022: 96 · 2021: 70 · 2020: 22
- FWCI
- 28.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81788101, 81661128007, 81530080, 81773062)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- gasdermin E, pyroptosis, chimeric antigen receptor T cells, cytokine release syndrome, macrophage activation, inflammatory cytokines, target cell death, adoptive T cell therapy
- MeSH terms
- Pyroptosis, Cytokine Release Syndrome, Gasdermins, Animals, Female, Humans, Macrophages, T-Lymphocytes, Leukemia, B-Cell, Immunotherapy, Adoptive, Phosphate-Binding Proteins, Cell Line, Tumor, Intracellular Signaling Peptides and Proteins, Mice, Granzymes, Perforin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.